1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Japan Medical Dynamic Marketing, Inc.

Japan Medical Dynamic Marketing, Inc.

JMDMF
Japan Medical Dynamic Marketing, Inc.US flagOther OTC
5.00
USD
- -
- -
156.35MMarket Cap
Japan Medical Dynamic Marketing, Inc.
JMDMF
(Other OTC)

Recent

price

5.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
373.91
360.19
307.4
357.48
448.02
492.22
515.73
560.89
633.64
685.11
634.41
727.46
808.6
880.5
951.71
907.78
464.35
Revenue per Share
-89.12
2.69
-15.04
10.83
-14.8
30.25
42.78
53.99
75.17
82.02
63.09
80.95
54.03
48.31
-17.5
9.99
34.64
Basic EPS, GAAP
94.99
34.22
2.33
-67.55
34.33
-1.09
36.37
58.54
10.36
35.83
46.54
57.86
33.04
11.49
-23.49
-68
- -
Free Cash Flow per Basic Share
5
4.98
5.02
5.01
5.02
5.01
6.03
7.01
7.99
9.02
10.02
11
12.04
13.07
14.06
15.07
- -
Dividend per Share
340.06
337.75
305.98
311.82
292.02
317.28
354.46
401.8
468.94
542.06
595.34
665.26
708.04
744.05
710.68
706.73
748.72
Book Value per Share
435.13
432.15
405.68
412.27
405.43
423.92
461.11
499.15
570.09
633.12
699.62
803.49
873.91
964.33
921.28
948.8
938.58
Tangible Book Value per Share
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
Basic Weighted Avg Shares
9,894
9,531
8,134
9,459
11,855
13,025
13,630
14,808
16,729
18,083
16,738
19,193
21,308
23,178
25,114
23,917
12,225
Sales/Revenue/Turnover
23.65
21.02
-1.87
6.99
10.93
13.11
14.01
13.81
13.36
14.62
12.96
13.87
9.5
7.54
6.2
2.4
9.24
Operating Margin (%)
960
826
805
927
1,102
894
930
1,015
1,162
1,389
1,389
1,421
1,550
1,595
1,671
1,614
689
Depreciation Expense
-2,358
71
-398
287
-392
801
1,131
1,425
1,985
2,165
1,665
2,136
1,424
1,272
-462
263
912
Net Income, GAAP
- -
58.01
- -
30.66
138.77
33.88
28.24
17.02
7.93
16.37
17.38
22.11
18.88
20.24
- -
44.31
13.44
Effective Tax Rate (%)
-23.84
0.75
-4.89
3.03
-3.3
6.15
8.3
9.63
11.86
11.97
9.94
11.13
6.68
5.49
-1.84
1.1
7.46
Profit Margin (%)
5,297
5,641
5,322
6,604
7,075
6,855
7,493
7,818
9,660
12,119
13,478
15,147
16,348
17,552
16,608
17,179
17,090
Working Capital
85
378
1,751
2,710
2,221
1,912
1,598
837
1,615
2,408
2,059
1,259
790
294
112
938
182
LT Debt
11,654
11,568
10,838
11,052
10,854
11,331
12,288
13,263
15,234
16,993
18,713
21,491
23,292
25,604
24,741
25,428
24,889
Total Equity
- -
5.01
- -
2.84
-2.94
6.58
7.63
9.26
10.85
10.73
8.27
9.08
6.69
5.28
- -
1.07
3.62
Return on Invested Capital (%)
- -
0.8
- -
2.89
-3.28
6.34
8.15
9.83
12.85
12.46
9
11.22
7.1
6.04
- -
1.56
4.17
Return on Capital (%)
-23.02
0.79
-4.67
3.51
-4.9
9.93
12.73
14.27
17.27
16.22
11.09
12.84
7.86
6.65
-2.41
1.41
4.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,200
- -
2,264
LT Borrowings
260
- -
167
LT Finance Leases
35
- -
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
- -
26
Market Capitalization
46,802
49,799
19,641

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
21,583
- -
21,565
Cash, Cash Equivalents & STI
2,322
- -
2,260
Accounts Receivable, Net
5,915
- -
5,357
Inventories
13,092
- -
13,407
Total Current Liabilities
4,031
- -
4,475
Payables & Accruals
- -
- -
- -
ST Debt
1,200
- -
2,264
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.54%
6.51%
2.77%
Free Cash Flow
-336.32%
-39.97%
189%
Net Income, GAAP
-21.65%
-61.8%
-156.98%
Sales/Revenue/Turnover
6.5%
7.61%
-4.77%
Total Cash Common Dividend
11.67%
8.46%
6.96%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,403
5,550
6,042
6,184
23,178
2025
- -
- -
- -
- -
25,114
2026
- -
- -
- -
- -
23,917

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.74
- -
- -
- -
48.31
2025
- -
- -
- -
- -
-17.5
2026
- -
- -
- -
- -
9.99

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
13.07
2025
- -
- -
- -
- -
14.06
2026
- -
- -
- -
- -
15.07
Similar Companies
Hamilton Thorne Ltd. (HTLZF)
enVVeno Medical Corporation (NVNO)
Brain Scientific Inc. (BRSF)
Dror Ortho-Design, Inc. (DROR)
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK)
Helius Medical Technologies, Inc. (HSM.TO)
Business
Japan Medical Dynamic Marketing, Inc. engages in the innovation, production, importation, and distribution of sophisticated medical devices across Japan and the United States. The company delivers a range of orthopedic products, including trauma implants like nails, screws, and plates designed for surgical fixation of fractures. They also offer joint prostheses intended to replace compromised natural joints and restore essential function lost to illness or injury, alongside spinal stabilization systems for use in spinal instability procedures. Additionally, their portfolio encompasses artificial bone void fillers for addressing bone defects suchs as those from fractures or tumors. Serving medical practitioners and hospitals, particularly within the orthopedic sector, the company emphasizes a unique business model that combines aspects of a trading firm with a focus on development-driven manufacturing. Founded in 1973 and based in Tokyo, Japan, the firm maintains a presence in the healthcare equipment and supplies industry. In recent financial disclosures, the company revised its earnings forecast for the fiscal year ending March 2026, anticipating increased sales from its "Trivicta Hip Stem" in the U.S. market, though projecting negative impacts on profitability due to supply chain challenges with outsourced knee joint products and escalating costs. The prior fiscal year, ending March 2025, saw a loss attributable to owners of the parent, partly stemming from a legal settlement involving its U.S. subsidiary. More recently, in November 2025, a former sales official was arrested alongside a University of Tokyo Hospital doctor on bribery allegations concerning preferential use of the company's devices.